 | | Vol. 15.38 – 28 September, 2023 |
| |
|
|
| Scientists established a large-scale multi-omics cohort of 579 patients with hormone receptor-positive /human epidermal growth factor receptor 2-negative (HER2−) breast cancer and identified the four molecular subtypes.
[Nature Genetics] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators described a method of delivery of doxorubicin using a novel tumor-homing peptide-based albumin nanoparticle system to TNBC.
[ACS Applied Materials & Interfaces] |
|
|
|
| To understand the effects of pentraxin-3 (PTX3) in TNBC, different cell lines were engineered to knock-down or overexpress PTX3. The contribution of tumor and stromal cells to PTX3 production in TNBC was also assessed.
[Experimental Hematology & Oncology] |
|
|
|
| To elucidate the mechanism of ALDH1A3-mediated breast cancer metastasis, scientists assessed the effect of aldehyde dehydrogenase 1A3 (ALDH1A3) on the expression of proteases and the regulators of proteases that degrade the extracellular matrix.
[Molecular Oncology] |
|
|
|
| Investigators reported that combining palbociclib with the STAT3 inhibitor nifuroxazide uncoupled senescence-associated secretory phenotype production from senescence-associated cell cycle exit.
[Cell Death Discovery] |
|
|
|
| Scientists aimed at providing new mechanistic and biological discoveries knocking out G protein-coupled estrogen receptor (GPER) expression by CRISPR/Cas9 technology in MDA-MB-231 TNBC cells.
[Cell Death Discovery] |
|
|
|
| The authors showed a role for decreased A2B1-regulated miRNAs in endocrine resistance and upregulation of the serine synthesis pathway to promote tumor progression in estrogen receptor α breast cancer.
[Endocrine-Related Cancer] |
|
|
|
| Researchers found that TNBC displayed the most abundant immunoglobulin-like transcript 4 (ILT4) expression among all breast cancer subtypes.
[Journal of Cell Science] |
|
|
|
| Scientists evaluated the effects of taraxerol on the migration and invasion of MDA-MB-231 cells, analyzed the molecular mechanism through network pharmacology and molecular docking, and finally verified it by in vitro experiments.
[PLOS One] |
|
|
|
|
| Investigators introduce Ginsenoside’s mechanism and research significance in achieving the therapeutic effect of breast cancer by changing the functional hallmarks of tumor cells.
[Chinese Medicine] |
|
|
|
|
| The Menarini Group and Therapeutics Inc. announced today that the European Commission has approved ORSERDU®. With this approval, ORSERDU becomes the first and only therapy specifically indicated for the treatment of estrogen receptor (ER)+, HER2– tumors that harbor ESR1 mutations.
[Menarini] |
|
|
|
|
| November 7 – 8, 2023
London, England, United Kingdom |
|
|
|
|
|
| | Cold Spring Harbor Laboratory – Cold Spring Harbor, New York, United States |
|
|
|
| | Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
